Inmed Stock Performance

INM
 Stock
  

USD 2.85  0.17  6.34%   

The company retains a Market Volatility (i.e., Beta) of 1.5132, which attests to a somewhat significant risk relative to the market. Let's try to break down what Inmed's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Inmed Pharmaceuticals will likely underperform. Even though it is essential to pay attention to Inmed Pharmaceuticals current price history, it is always good to be careful when utilizing equity current price movements. Our philosophy towards determining any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Inmed Pharmaceuticals exposes twenty-one different technical indicators, which can help you to evaluate its performance. Inmed Pharmaceuticals has an expected return of -0.16%. Please be advised to check out Inmed Pharmaceuticals coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Inmed Pharmaceuticals performance from the past will be repeated at some point in the near future.
  
Inmed Performance
0 of 100
Over the last 90 days Inmed Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with latest conflicting performance, the Stock's basic indicators remain steady and the new chaos on Wall Street may also be a sign of medium-term gains for the company stakeholders. ...more

Structure and Payout Changes

Last Split Factor
1:25
Dividend Date
2020-07-06
Last Split Date
2022-09-07

Inmed Price Channel

Quick Ratio2.85
Fifty Two Week Low2.4000
Target High Price20.00
Fifty Two Week High54.5000
Target Low Price20.00

Inmed Pharmaceuticals Relative Risk vs. Return Landscape

If you would invest  600.00  in Inmed Pharmaceuticals on August 28, 2022 and sell it today you would lose (315.00)  from holding Inmed Pharmaceuticals or give up 52.5% of portfolio value over 90 days. Inmed Pharmaceuticals is generating negative expected returns assuming volatility of 15.0415% on return distribution over 90 days investment horizon. In other words, majority of equities are less volatile than Inmed, and most equities are expected to generate higher returns over the next 90 days.
  Daily Expected Return (%)  
       Risk (%)  
Considering the 90-day investment horizon Inmed Pharmaceuticals is expected to under-perform the market. In addition to that, the company is 10.95 times more volatile than its market benchmark. It trades about -0.01 of its total potential returns per unit of risk. The DOW is currently generating roughly 0.08 per unit of volatility.

Inmed Pharmaceuticals Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Inmed Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Inmed Pharmaceuticals, and traders can use it to determine the average amount a Inmed Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.0103

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative ReturnsINM
Estimated Market Risk
 15.04
  actual daily
 
 96 %
of total potential
 
9696
Expected Return
 -0.16
  actual daily
 
 0 %
of total potential
 
00
Risk-Adjusted Return
 -0.01
  actual daily
 
 0 %
of total potential
 
00
Based on monthly moving average Inmed Pharmaceuticals is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Inmed Pharmaceuticals by adding it to a well-diversified portfolio.

About Inmed Pharmaceuticals Performance

To evaluate Inmed Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Inmed Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Inmed Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Inmed Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Inmed's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada. Inmed Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.

Things to note about Inmed Pharmaceuticals

Checking the ongoing alerts about Inmed Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Inmed Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Inmed Pharmaceuticals Alerts

Equity Alerts and Improvement Suggestions

Inmed Pharmaceuticals generated a negative expected return over the last 90 days
Inmed Pharmaceuticals has high historical volatility and very poor performance
Inmed Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported the last year's revenue of 1.41 M. Reported Net Loss for the year was (19.14 M) with profit before taxes, overhead, and interest of 543.55 K.
Inmed Pharmaceuticals has about 9.35 M in cash with (15.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.98, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Latest headline from MacroaxisInsider: Disposition of 15000 shares by Adams Eric A of Inmed Pharmaceuticals subject to Rule 16b-3
Please see Risk vs Return Analysis. You can also try Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for analysis

When running Inmed Pharmaceuticals price analysis, check to measure Inmed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inmed Pharmaceuticals is operating at the current time. Most of Inmed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Inmed Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inmed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Inmed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Is Inmed Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inmed Pharmaceuticals. If investors know Inmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inmed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
3.1 M
Return On Assets
(0.56) 
Return On Equity
(1.46) 
The market value of Inmed Pharmaceuticals is measured differently than its book value, which is the value of Inmed that is recorded on the company's balance sheet. Investors also form their own opinion of Inmed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inmed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inmed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inmed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Inmed Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.